Literature DB >> 1576284

Asymptomatic intestinal colonization by pathogenic Entamoeba histolytica in amebic liver abscess: prevalence, response to therapy, and pathogenic potential.

E M Irusen1, T F Jackson, A E Simjee.   

Abstract

Since the application of isoenzyme electrophoresis to the study of Entamoeba histolytica, the prevalence and natural history of asymptomatic intestinal colonization in patients with amebic liver abscess (ALA) has not been addressed. We prospectively evaluated this enteric phase in 50 patients with ALA, using two dosage regimens of metronidazole. The overall prevalence of asymptomatic colonization was 72% (36/50). All these isolates, without exception, proved to express pathogenic zymodemes. Despite a 100% clinical response of the hepatic lesions, failure to eradicate the organism from the bowel occurred in 20 of these 36 subjects. During longitudinal posttreatment surveillance, three carriers returned with second bouts of invasive disease: one with dysentery and two with liver abscesses. Thus, in patients with ALA, there is a high prevalence of intestinal colonization with exclusively pathogenic strains, and treatment with metronidazole frequently results in a continued carrier state. These carriers have a propensity for developing recurrent invasive disease and constitute a public health hazard.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1576284     DOI: 10.1093/clinids/14.4.889

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

1.  Comparison of use of enzyme-linked immunosorbent assay-based kits and PCR amplification of rRNA genes for simultaneous detection of Entamoeba histolytica and E. dispar.

Authors:  D Mirelman; Y Nuchamowitz; T Stolarsky
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

Review 2.  [Therapy of tropical diseases after returning from travel].

Authors:  G D Burchard; H Sudeck
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

3.  Entamoeba moshkovskii is associated with diarrhea in infants and causes diarrhea and colitis in mice.

Authors:  Chikako Shimokawa; Mamun Kabir; Mami Taniuchi; Dinesh Mondal; Seiki Kobayashi; Ibne Karim M Ali; Shihab U Sobuz; Masachika Senba; Eric Houpt; Rashidul Haque; William A Petri; Shinjiro Hamano
Journal:  J Infect Dis       Date:  2012-06-21       Impact factor: 5.226

4.  The invasiveness of Entamoeba histolytica - a continuing enigma.

Authors:  J P Ackers
Journal:  Clin Mol Pathol       Date:  1996-08

5.  Mucosal immunity to asymptomatic Entamoeba histolytica and Entamoeba dispar infection is associated with a peak intestinal anti-lectin immunoglobulin A antibody response.

Authors:  Mohamed D Abd-Alla; Terry F G H Jackson; Tyson Rogers; Selvan Reddy; Jonathan I Ravdin
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

6.  Neutralizing monoclonal antibody epitopes of the Entamoeba histolytica galactose adhesin map to the cysteine-rich extracellular domain of the 170-kilodalton subunit.

Authors:  B J Mann; C Y Chung; J M Dodson; L S Ashley; L L Braga; T L Snodgrass
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

7.  Efficacy of antiamebic drugs in a mouse model.

Authors:  Stephen Becker; Paul Hoffman; Eric R Houpt
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

8.  Amebic Liver Abscess.

Authors:  Wolfram Goessling; Raymond T. Chung
Journal:  Curr Treat Options Gastroenterol       Date:  2002-12

9.  A review of amoebic liver abscess for clinicians in a nonendemic setting.

Authors:  Terry Wuerz; Jennifer B Kane; Andrea K Boggild; Sigmund Krajden; Jay S Keystone; Milan Fuksa; Kevin C Kain; Ralph Warren; John Kempston; Joe Anderson
Journal:  Can J Gastroenterol       Date:  2012-10       Impact factor: 3.522

Review 10.  Laboratory diagnosis of amebiasis.

Authors:  Mehmet Tanyuksel; William A Petri
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.